Top Page
Island Pharmaceuticals Ltd
(Sydney:ILA)
Island Pharmaceuticals Ltd (ILA) vs. iShares MSCI Australia ETF (EWA)
Island Pharmaceuticals Ltd Business Overview & Revenue Model
Island Pharmaceuticals Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 118.91K | 118.91K | 1.25M | 11.06K | 0.00 | 0.00 |
| Gross Profit | -1.29M | -1.29M | -1.01M | 11.06K | 0.00 | 0.00 |
| EBITDA | 0.00 | 0.00 | -2.82M | -2.82M | -2.61M | -2.13M |
| Net Income | -3.92M | -3.92M | -2.86M | -2.83M | -2.61M | -2.13M |
Balance Sheet | ||||||
| Total Assets | 7.49M | 7.49M | 2.56M | 2.05M | 4.90M | 6.64M |
| Cash, Cash Equivalents and Short-Term Investments | 7.25M | 7.25M | 1.66M | 2.00M | 4.79M | 6.46M |
| Total Debt | 0.00 | 0.00 | 421.97K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 336.43K | 336.43K | 1.05M | 263.85K | 580.73K | 236.83K |
| Stockholders Equity | 7.16M | 7.16M | 1.52M | 1.79M | 4.32M | 6.40M |
Cash Flow | ||||||
| Free Cash Flow | -2.77M | -2.77M | -3.16M | -2.71M | -1.88M | -938.24K |
| Operating Cash Flow | -2.77M | -2.77M | -3.16M | -2.71M | -1.88M | -938.24K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 77.37K |
| Financing Cash Flow | 8.36M | 8.36M | 2.79M | -171.36K | 0.00 | 7.30M |
Island Pharmaceuticals Ltd Technical Analysis
Island Pharmaceuticals Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$150.56M | -15.21 | -41.51% | ― | -40.74% | -21.21% | |
50 Neutral | AU$81.92M | -7.85 | -138.54% | ― | ― | 16.61% | |
50 Neutral | AU$88.33M | -9.12 | -49.72% | ― | ― | 10.78% | |
44 Neutral | AU$36.58M | -7.94 | -16.65% | ― | ― | -672.73% | |
43 Neutral | AU$115.69M | -19.25 | -90.37% | ― | ― | 26.38% | |
42 Neutral | AU$60.00M | -8.40 | -159.86% | ― | 110.44% | 35.90% |
Island Pharmaceuticals Ltd Corporate Events
Island Pharmaceuticals Ltd has secured a Master Service Agreement with Texas Biomedical Research Institute, a leading BSL-4 facility in the USA, to advance the development of its antiviral candidate, Galidesivir. This agreement enables potential non-human primate studies crucial for the FDA’s Animal Rule development pathway, following positive FDA engagement confirming eligibility and potential for a Priority Review Voucher post-approval. The collaboration with Texas Biomed, known for its expertise in high-containment infectious disease research, is a strategic move to progress Galidesivir towards FDA approval, while the company continues to seek additional research partners.
Island Pharmaceuticals Ltd has been granted a US patent for the use of Galidesivir in treating SARS-CoV-2, extending its patent protection until July 2042. This development strengthens Island’s intellectual property portfolio and supports Galidesivir’s potential as a broad-acting antiviral, aligning with the company’s strategy to advance its regulatory pathway for combating the Marburg virus.
Island Pharmaceuticals Ltd has completed an additional submission to the FDA as part of its ongoing efforts to optimize the development program for its antiviral drug, Galidesivir. This submission follows the FDA’s confirmation that Galidesivir is eligible for the Animal Rule pathway, a significant step that reduces regulatory risk and advances the drug’s development for Marburg virus. The company anticipates a response from the FDA by early January 2026, which will guide the finalization of their study design and facilitate the commencement of a Marburg study in the first quarter of 2026.
Island Pharmaceuticals Ltd has announced a change in the director’s interest, specifically involving Christopher Ntoumenopoulos. The notice details the acquisition and disposal of options and shares held by the director, reflecting adjustments in his financial stake in the company. This change may impact the company’s governance and stakeholder perceptions, particularly as it aligns with the company’s strategic focus on advancing its pharmaceutical products through regulatory milestones.
Island Pharmaceuticals Ltd has secured approximately $1 million in new funding through the exercise of options by directors and substantial shareholders. This capital injection enhances the company’s financial position, supporting the clinical development and commercial readiness of Galidesivir, a broad-spectrum antiviral. The funding will aid regulatory initiatives under the FDA Animal Rule and US Government engagement, positioning Galidesivir for potential inclusion in national stockpiles as a critical antiviral countermeasure. The investment reflects confidence in Island’s strategy and its ability to advance Galidesivir towards potential approval and strategic value creation.
Island Pharmaceuticals Limited has announced the issuance of 14,428,970 fully paid ordinary shares following the exercise of unlisted options at $0.07 per share. This move, executed without disclosure under Part 6D.2 of the Corporations Act, reflects the company’s compliance with relevant regulatory provisions, potentially enhancing its capital structure and market positioning.
Island Pharmaceuticals Ltd has announced the quotation of 14,428,970 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective December 3, 2025. This move is part of the company’s strategic efforts to expand its financial base and enhance its market presence, potentially impacting its operations and positioning within the pharmaceutical industry.
Island Pharmaceuticals Ltd has been accepted into the Medical Countermeasures Coalition (MC2), a significant step in advancing its antiviral drug, Galidesivir, as a priority countermeasure. This membership is expected to bolster the company’s regulatory, clinical, and stockpiling efforts, enhancing its engagement with the US Government and positioning it alongside major biotechnology firms in the coalition.
Island Pharmaceuticals Ltd has appointed Todd Strategy Group, a Washington DC-based government affairs firm, to enhance its engagement with the US government in the biodefense and health security sectors. This collaboration aims to position Galidesivir as a critical countermeasure against viral threats like Marburg and to strengthen Island’s commercial readiness for clinical trials and FDA interactions. The partnership is expected to provide strategic insights into federal processes and potential funding pathways, aligning with Island’s strategy to advance its antiviral programs and secure US government support.
Island Pharmaceuticals Ltd announced that the US FDA has agreed to the Animal Rule pathway for the development of Galidesivir as a countermeasure against the Marburg virus. This pathway, along with the potential eligibility for a Priority Review Voucher, significantly de-risks and accelerates the regulatory process for the drug. The FDA’s guidance on the clinical program design will enable Island Pharmaceuticals to finalize its plans for trial commencement in early 2026. The positive feedback from the FDA underscores the strength of Galidesivir’s historical data, which showed a 94% survival rate in Marburg-infected primates. The company is advancing agreements with potential trial sites and engaging with the US government to further its strategy of including Galidesivir in national stockpiles, which could create substantial strategic and financial value for stakeholders.
Island Pharmaceuticals Ltd has announced a change in its registered office and principal place of business to a new address in Hawthorn East, Melbourne. This move is part of the company’s ongoing efforts to streamline operations as it continues to develop its lead asset, ISLA-101, which has potential implications for the treatment of dengue fever and could expedite FDA approval processes, enhancing the company’s market positioning.
Island Pharmaceuticals Ltd announced an upcoming webinar to discuss the FDA’s response regarding Galidesivir’s development and approval pathway, including its eligibility for a Priority Review Voucher and pending clinical initiatives. This announcement highlights the company’s efforts to advance Galidesivir, a broad-spectrum antiviral, which could significantly impact its operations and positioning in the antiviral drug market, addressing critical unmet medical needs.
Island Pharmaceuticals Ltd has requested a trading halt on its securities on the Australian Securities Exchange pending an announcement related to feedback from the US Food & Drug Administration on its Galidesivir program. This move is intended to manage disclosure obligations and maintain an orderly market, reflecting the company’s proactive approach in handling significant regulatory feedback that could impact its operations and market perception.
Island Pharmaceuticals Ltd has announced a change in the director’s interest, specifically concerning Christopher Ntoumenopoulos. The change involves the acquisition of options tied to the company’s securities, with specific vesting conditions related to FDA approvals. This move could potentially impact the company’s strategic positioning and stakeholder interests, reflecting a focus on advancing their pharmaceutical developments.
Island Pharmaceuticals Ltd has announced the issuance of 10,500,000 unquoted securities under an employee incentive scheme, with these securities not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize employees, potentially impacting its operational dynamics and aligning employee interests with corporate goals.
Island Pharmaceuticals Ltd announced a change in the director’s interest, with Dr. David Foster acquiring an additional 160,000 ordinary shares, increasing his total holdings. This acquisition, approved by shareholders at the recent Annual General Meeting, reflects confidence in the company’s future prospects and may influence stakeholder perceptions positively.
Island Pharmaceuticals Limited has issued 666,666 fully paid ordinary shares at $0.15 per share following shareholder approval during their Annual General Meeting. This move, executed without disclosure under Part 6D.2 of the Corporations Act, signifies compliance with relevant legal provisions and indicates the company’s strategic efforts to strengthen its financial position.
Island Pharmaceuticals Ltd has completed the acquisition of the Galidesivir antiviral program from BioCryst Pharmaceuticals, aiming to expedite its FDA approval using the Animal Rule for fast-tracking. The acquisition is part of Island’s strategy to position Galidesivir as a critical countermeasure against viral threats like Marburg and Ebola, supported by strong historical data showing high survival rates in non-human primates. The company is also negotiating strategic partnerships for upcoming animal studies and has secured additional funding through shareholder support, enhancing its financial flexibility for near-term projects.
Island Pharmaceuticals Ltd announced that the US FDA has confirmed the timeline for providing feedback on the clinical development and approval pathway for Galidesivir, an antiviral drug. Despite recent US Government shutdowns, the FDA aims to deliver responses by 12 November 2025, which will include alignment on the use of the Animal Rule to expedite Galidesivir’s approval in Marburg, study design clarification, and potential for a Priority Review Voucher. This development underscores the importance of Galidesivir in public health and the company’s strong communication with the FDA, as it continues negotiations for an animal study in Marburg.
Island Pharmaceuticals Ltd has announced the quotation of 180,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of October 17, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially improve its market positioning, providing opportunities for stakeholders and investors to engage with the company’s growth trajectory.
Island Pharmaceuticals Ltd held its Annual General Meeting, where several resolutions were passed, including the adoption of the remuneration report, election of a new director, and approval of increased placement capacity. These decisions are likely to impact the company’s strategic direction and operational capabilities, potentially enhancing its market positioning and stakeholder value.
Island Pharmaceuticals Ltd has announced the issuance of 600,000 unquoted securities under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize employees and align their interests with the company’s growth objectives, potentially impacting its operational dynamics and stakeholder engagement.